Europe Urges Strategic Moves to Boost Biosimilar Medicine Impact
Europe stands at a pivotal moment as biologic drugs approach the end of their market exclusivity, presenting a significant opportunity to enhance healthcare access...
IQVIA Unveils Groundbreaking AI Assistant, Revolutionizing Healthcare and Life Sciences Insights
Key TakeawaysIQVIA introduces a generative AI tool, IQVIA AI Assistant, offering real-time analytics for life sciences and healthcare industries.
Powered by IQVIA Healthcare-grade...
Cancer Cases Soar as Innovation Explodes, but Equity in Access Remains Elusive
A new report by the IQVIA Institute for Human Data Science paints a complex picture of the future of cancer treatment. It's a story...
Global R&D 2024 Report: Future of Biomedical Research and Development in the Post-Pandemic Era
The "Global Trends in R&D 2024" report outlines the current state and future directions of biomedical research and development, underlining the resilience and adaptability...
Enhancing EU Healthcare Access: Urgency for More Biologic Competition and Biosimilars Medicines
The future landscape of healthcare systems in Europe is poised for a transformation led by biosimilar medicines. Forecasts indicate that by 2032, biosimilars will...
New Report Reveals Disparities in Adult Vaccine Access and Uptake Across Global Cities
A new report from the IQVIA Institute for Human Data Science, funded by GSK in collaboration with the Global Coalition on Aging (GCOA), sheds...
IQVIA Report Highlights EU’s Chance to Cultivate Sustainable Biosimilar Competition
The European Union (EU) is in the process of reviewing its pharmaceutical legislation, and a recent IQVIA white paper titled "Assessing the Biosimilar Void"...
